Kymera Investor Day Presentation Deck

KYMERA KYMERA ©2021 KYMERA THERAPEUTICS, INC. Introduction to Kymera ● ● ● ● ● ● Leader in Targeted Protein Degradation (TPD) Building a fully-integrated, global biotech company and Oncology, but Initial focus in Immunology/Inflammation already a disease-agnostic platform Accelerating forward integration through key strategic partnerships Establishing many "firsts" for TPD with initial programs Three programs in/entering the clinic and a deep pipeline positioned to deliver ≥1 IND/year Focused on continued innovation in platform and discovery Well capitalized with $611 million of cash* KYMERA R&D DAY - December 16th, 2021 * Based on reported cash at September 30, 2021 PAGE 11

View entire presentation